Evidence map›Paper›PMID 26404098›Full record

ReviewHeart failure reviews2015

Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.

Carolyn L Lekavich, Debra J Barksdale, Virginia Neelon, Jia-Rong Wu

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04233086 (A Retrospective Observational Analysis of a Cohort With Heart Failure With Preserved Ejection Fraction From a BNP Pathway Clinic), which is not on this map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04233086 completednot on this mapstarted 2020, after this paper: background citation

A Retrospective Observational Analysis of a Cohort With Heart Failure With Preserved Ejection Fraction From a BNP Pathway Clinic

TypeobservationalSponsorPortsmouth Hospitals NHS TrustRan2020 to 2020Enrolled500ConditionsHeart Failure With Preserved Ejection FractionArmsNo intervention, observational only
3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Trial
  2. Article
  3. Comparison of beta-blockersWorld journal of cardiology · 2025
    Article
  4. When in doubt, pig it out: a versatile translational platform to study CKD, HFpEF, and CKM syndrome.American journal of physiology. Heart and circulatory physiology · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carolyn L LekavichDivision of Cardiovascular Medicine, Duke University Medical Center, Duke North, Erwin Road, Suite 7400, DUMC Box 3126, Durham, NC, 27710, USA. carolyn.lekavich@duke.edu.
Debra J BarksdaleSchool of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Virginia NeelonBiobehavioral Laboratory, School of Nursing, University of North Carolina, Chapel Hill, NC, USA.
Jia-Rong WuSchool of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the USA, 5.7 million Americans ≥20 years have heart failure (HF) and heart failure preserved ejection fraction (HFpEF) accounts for at least 50 % of all hospital admissions for HF. HFpEF has no single guideline for diagnosis or treatment, the patient population is heterogeneously and inconsistently described, and longitudinal studies are lacking. The primary aims of this manuscript were to present an integrated review of the current state of the science on HFpEF, demonstrate gaps in the literature and provide the rationale for the design and implementation of future research to yield insights into the syndrome of HFpEF. The scientific literature was comprehensively reviewed on HFpEF pathophysiology, patient characteristics, diagnostic criteria, echocardiography biomarkers, treatment approaches and outcomes. Discrepancies in patient characteristics, diagnostic criteria, study methods and echocardiographic biomarkers were identified. This review indicates that no single test or guideline exists for diagnosis or treatment for HFpEF; heterogeneity of the population is complicated by multiple comorbidities that factor into etiology, race and age are likely important factors that define the phenotype, and limited information is available that designates early markers of impending HFpEF. Studies designed and adequately powered to study the impact of race and age along with consistent use of HFpEF diagnostic criteria are critically needed to further incident HFpEF research.

Indexed as

Adrenergic beta-AntagonistsBiomarkersCalcium Channel BlockersComorbidityEchocardiographyElectrophysiologyExerciseHeart FailureHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMineralocorticoid Receptor AntagonistsStroke VolumeAdrenergic beta-AntagonistsBiomarkersCalcium Channel BlockersHydroxymethylglutaryl-CoA Reductase InhibitorsMineralocorticoid Receptor AntagonistsDiagnostic guidelinesDiastolic heart failureHeart failure preserved ejection fraction (HFpEF)Treatment

Identifiers

PMID26404098

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.